Clinical trials: acne
Acne Vulgaris
A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
This is a 12 week, multi-site, double-blind, vehicle-controlled study in subjects with mild to moderate facial acne. Subjects will be randomized 1:1 to apply either topical NAG or vehicle gel daily.
- Trial name
- NCT02404285
- Testing
- Next Science Acne Gel, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Next Science TM
Acne Vulgaris
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
- Trial name
- NCT00660985
- Testing
- Adapalene
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Galderma R&D
Primary Anatomic or Reverse Total Shoulder Arthroplasty
Hydrogen Peroxide to the Wound Following Surgical Incision Affecting Cultures in Primary Shoulder Arthroplast
Cutibacterium acnes has been the focus of much recent shoulder literature, as it has been found to be both a common cause of periprosthetic joint infection as well as a common contaminant in shoulder surgery.
- Trial name
- NCT04609306
- Testing
- H2O2 application to incision
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Florida
Hidradenitis Suppurativa
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens…
- Trial name
- NCT04179175
- Testing
- secukinumab
- Where
- 191 sites in United States, Argentina and 36 more
- Volunteers
- 702 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER (OLE) (NCT01635764)
- Testing
- adalimumab
- Volunteers
- 508 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Acne Vulgaris
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12.
- Trial name
- NCT00422240
- Testing
- Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%
- Where
- United States
- Volunteers
- 1,668 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne…
- Trial name
- NCT02886715
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Where
- 25 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Acne Vulgaris
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
- Trial name
- NCT03168334
- Testing
- IDP-123 Lotion, IDP-123 Vehicle Lotion
- Where
- 45 sites in United States, Canada
- Volunteers
- 801 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Rosacea
Effects of PRK 124 Lotion in Acne Rosacea
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial…
- Trial name
- NCT00580723
- Testing
- PRK 124
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Irvine
Acne Vulgaris
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
- Trial name
- NCT02959970
- Testing
- dapsone gel
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Almirall, S.A.
Acne
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
The primary objective of this study is to compare the efficacy and safety and tolerability of ACYC Gel and vehicle in the treatment of subjects with Acne Vulgaris.
- Trial name
- ACYC (NCT01701024)
- Testing
- ACYC, ACYC vehicle
- Where
- 24 sites in United States
- Volunteers
- 498 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
- Trial name
- NCT04892706
- Testing
- IDP-126 Gel, IDP-126 Vehicle Gel, Epiduo® Forte Gel
- Where
- 42 sites in United States, Belgium and 1 more
- Volunteers
- 686 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
A Study of Acne Treatment in Children Ages 9 to 11
A study to determine if using Retin-A Micro 0.04% as facial acne treatment in patients ages 9 to 11 is safe and efficacious.
- Trial name
- NCT00907335
- Testing
- Retin-A Micro 0.04% facial acne treatment, Vehicle control
- Where
- 12 sites in United States
- Volunteers
- 110 people
- Sponsor
- Bausch Health Americas, Inc.
Acne
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
- Trial name
- NCT00841776
- Testing
- Duac, Ziana gel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Stiefel, a GSK Company
Hidradenitis Suppurativa
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- NCT05216224
- Testing
- ATI-450
- Where
- 20 sites in United States
- Volunteers
- 95 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acne Vulgaris
A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris
This study is intended to evaluate the efficacy and safety of Visonac Photodynamic Therapy (PDT) in patients with severe acne, score 4 on global IGA scale.
- Trial name
- NCT01347879
- Testing
- Visonac PDT, Vehicle cream with PDT
- Where
- 15 sites in United States
- Volunteers
- 153 people
- Sponsor
- Photocure
Acne Vulgaris
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
- Trial name
- NCT01773122
- Testing
- Dapsone Formulation A, Dapsone Formulation B, Dapsone Formulation C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Allergan
Acne Scars - Mixed Atrophic and Hypertrophic, Wrinkle
Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles
The objective of this clinical study is to evaluate the efficacy of fractional RF for the treatment and reduction of acne scarring or facial wrinkles.
- Trial name
- NCT04057768
- Testing
- Venus Viva
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Venus Concept
Severe Nodular Acne
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.
- Trial name
- NCT00975143
- Testing
- CIP-Isotretinoin, Isotretinoin
- Where
- 49 sites in United States, Canada
- Volunteers
- 925 people
- Sponsor
- Cipher Pharmaceuticals Inc.